Associations of functional human leucocyte antigen class I groups with HIV viral load in a heterogeneous cohort.


Journal

AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219

Informations de publication

Date de publication:
01 09 2023
Historique:
medline: 4 8 2023
pubmed: 3 8 2023
entrez: 3 8 2023
Statut: ppublish

Résumé

Human leucocyte antigen (HLA) class I alleles are the main host genetic factors involved in controlling HIV-1 viral load (VL). Nevertheless, HLA diversity has proven a significant challenge in association studies. We assessed how accounting for binding affinities of HLA class I alleles to HIV-1 peptides facilitate association testing of HLA with HIV-1 VL in a heterogeneous cohort. Cohort from the Strategic Timing of AntiRetroviral Treatment (START) study. We imputed HLA class I alleles from host genetic data (2546 HIV+ participants) and sampled immunopeptidomes from 2079 host-paired viral genomes (targeted amplicon sequencing). We predicted HLA class I binding affinities to HIV-1 and unspecific peptides, grouping alleles into functional clusters through consensus clustering. These functional HLA class I clusters were used to test associations with HIV VL. We identified four clades totaling 30 HLA alleles accounting for 11.4% variability in VL. We highlight HLA-B∗57:01 and B∗57:03 as functionally similar but yet overrepresented in distinct ethnic groups, showing when combined a protective association with HIV+ VL (log, β -0.25; adj. P-value < 0.05). We further demonstrate only a slight power reduction when using unspecific immunopeptidomes, facilitating the use of the inferred functional HLA groups in other studies. The outlined computational approach provides a robust and efficient way to incorporate HLA function and peptide diversity, aiding clinical association studies in heterogeneous cohorts. To facilitate access to the proposed methods and results we provide an interactive application for exploring data.

Identifiants

pubmed: 37534724
doi: 10.1097/QAD.0000000000003557
pii: 00002030-202309010-00002
pmc: PMC10399941
doi:

Substances chimiques

Histocompatibility Antigens Class I 0
HLA-B Antigens 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1643-1650

Subventions

Organisme : NIAID NIH HHS
ID : UM1 AI068641
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI120197
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI136780
Pays : United States
Organisme : Medical Research Council
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.

Références

Int J Immunogenet. 2021 Aug;48(4):317-325
pubmed: 34176210
Elife. 2020 Apr 02;9:
pubmed: 32238263
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
Proc Natl Acad Sci U S A. 2019 Jan 15;116(3):944-949
pubmed: 30602460
Trends Microbiol. 2015 Apr;23(4):212-24
pubmed: 25613992
Immunogenetics. 2016 Jul;68(6-7):401-416
pubmed: 27233953
Nat Methods. 2020 Mar;17(3):261-272
pubmed: 32015543
Clin Vaccine Immunol. 2013 Jul;20(7):1048-54
pubmed: 23677320
J Immunol. 2017 Nov 1;199(9):3360-3368
pubmed: 28978689
AIDS. 2021 Apr 1;35(5):783-789
pubmed: 33587436
J Infect Dis. 2021 Dec 15;224(12):2053-2063
pubmed: 33974707
Pharmacogenomics J. 2014 Apr;14(2):192-200
pubmed: 23712092
NPJ Vaccines. 2020 Feb 4;5:11
pubmed: 32047656
Science. 2014 Mar 21;343(6177):1243727
pubmed: 24653038
J Infect Dis. 2019 Sep 13;220(8):1325-1334
pubmed: 31219150
Cell Syst. 2021 Jan 20;12(1):102-107.e4
pubmed: 33321075
Int J Immunogenet. 2017 Oct;44(5):195-211
pubmed: 28877428
Immunogenetics. 2013 Sep;65(9):655-65
pubmed: 23775223
Nat Commun. 2017 Sep 19;8(1):599
pubmed: 28928442
Immunity. 2012 Sep 21;37(3):426-40
pubmed: 22999948
Elife. 2013 Oct 29;2:e01123
pubmed: 24171102
Mol Biol Evol. 2020 Mar 1;37(3):639-650
pubmed: 31651980
Sci Signal. 2016 Jun 14;9(432):re6
pubmed: 27303057
Bioinformatics. 2017 Feb 15;33(4):574-576
pubmed: 27797770
Nat Immunol. 2015 Jun;16(6):577-83
pubmed: 25988890
Nucleic Acids Res. 2019 Jul 2;47(W1):W256-W259
pubmed: 30931475
PLoS Comput Biol. 2017 Feb 9;13(2):e1005339
pubmed: 28182649
Hum Genet. 2020 Jun;139(6-7):777-781
pubmed: 31729546
Bioinformatics. 2015 Nov 15;31(22):3718-20
pubmed: 26209431
Sci Rep. 2018 Apr 17;8(1):6111
pubmed: 29666450
Curr Opin Immunol. 1998 Aug;10(4):478-82
pubmed: 9722926

Auteurs

Adrian G Zucco (AG)

PERSIMUNE Center of Excellence, Rigshospitalet.

Marc Bennedbæk (M)

Virus Research and Development Laboratory, Virus and Microbiological Special Diagnostics, Statens Serum Institut.

Christina Ekenberg (C)

PERSIMUNE Center of Excellence, Rigshospitalet.

Migle Gabrielaite (M)

Center for Genomic Medicine, Copenhagen University Hospital, Copenhagen, Denmark.

Preston Leung (P)

PERSIMUNE Center of Excellence, Rigshospitalet.

Mark N Polizzotto (MN)

Clinical Hub for Interventional Research, College of Health and Medicine, The Australian National University, Canberra, Australia.

Virginia Kan (V)

George Washington University, Veterans Affairs Medical Center, Washington, DC, USA.

Daniel D Murray (DD)

PERSIMUNE Center of Excellence, Rigshospitalet.

Jens D Lundgren (JD)

PERSIMUNE Center of Excellence, Rigshospitalet.

Cameron R MacPherson (CR)

PERSIMUNE Center of Excellence, Rigshospitalet.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH